Xilio Therapeutics, INC Form 4 insider transactions

Director Akintunde Olatokumbo Bello was granted 5,000 stock options in Xilio Therapeutics, Inc. on June 11, 2026.

Director James Samuel Shannon was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity incentive.

Director Daniel J. Curran was granted 5,000 stock options in Xilio Therapeutics, Inc. on June 11, 2026.

Director Xu Yuan was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of standard equity compensation.

Director Robert W. Ross was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of standard equity compensation.

Director Sara Bonstein was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Aoife Brennan was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity compensation package.

Director Cheryl R. Blanchard was granted 10,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity incentive.

Director James S. Shannon reported buying 5,000 Xilio shares at a weighted average $8.79, lifting his direct stake to 10,000 shares after a 1-for-14 reverse split.

Xilio Therapeutics' Chief Financial Officer, Christopher James Frankenfield, reported the exercise of restricted stock units, a 'sell to cover' transaction for tax obligations, and the grant of new stock options.

Xilio Therapeutics CEO Rene Russo reported the acquisition of 44,250 common shares from RSU conversion and a grant of 1,500,258 stock options.

Xilio Therapeutics' Chief Medical Officer, Katarina Luptakova, reported the vesting of restricted stock units and the grant and partial vesting of stock options.

Xilio Therapeutics' SVP of Finance and Accounting, Kevin M. Brennan, reported the acquisition of common stock from RSU conversion and a 'sell to cover' transaction for tax obligations.

Gilead Sciences, a 10% owner and director of Xilio Therapeutics, converted 13.3 million Series B Warrants into Prefunded Warrants, increasing its beneficial ownership.

Xilio Therapeutics' CFO, Christopher James Frankenfield, was granted 925,000 new stock options and had 848,172 existing options repriced to a lower exercise price of $1.50 per share.

Xilio Therapeutics has repriced certain stock options for SVP Kevin Brennan to $1.00 per share and approved a new 2025 Stock Incentive Plan.

Xilio Therapeutics' Chief Medical Officer, Katarina Luptakova, saw several stock options repriced to $1.50 per share and received a new grant of 625,000 options.

Xilio Therapeutics' CEO Rene Russo received a significant option repricing and a new stock option grant following stockholder approval of the 2025 Stock Incentive Plan.

A director at Xilio Therapeutics, Inc. has reported the acquisition of 70,000 shares of common stock through open market purchases in mid-June 2025, signaling increased insider confidence.

Xilio Therapeutics, Inc. President and CEO Rene Russo acquired 36,289 shares of common stock at a weighted average price of $0.6801, increasing her beneficial ownership to 281,172 shares.

Xilio Therapeutics, Inc.'s President and CEO, Rene Russo, filed an amended Form 4 to include a previously omitted power of attorney related to Section 16 reporting obligations.

Xilio Therapeutics, Inc. announced that Director Robert W. Ross was granted 31,000 stock options with an exercise price of $0.693, vesting fully by June 11, 2026 or the next annual meeting.

Xilio Therapeutics, Inc. Director Aoife Brennan was granted 31,000 stock options with an exercise price of $0.693, aligning her interests with shareholder value.

Xilio Therapeutics, Inc. Director Sara Bonstein was granted 31,000 stock options with an exercise price of $0.693, vesting fully by June 2026 or the next annual meeting.

Xilio Therapeutics, Inc. Director Daniel J. Curran was granted 31,000 stock options with an exercise price of $0.693 per share, vesting fully by June 11, 2026, or the next annual meeting.

Xilio Therapeutics, Inc. Director Paul J. Clancy was granted 31,000 stock options with an exercise price of $0.693, vesting over the next year, as reported in a recent SEC Form 4 filing.

Xilio Therapeutics, Inc. Director Yuan Xu has been granted 31,000 stock options with an exercise price of $0.693 per share, aligning executive incentives with shareholder value.

Xilio Therapeutics, Inc. Director James Samuel Shannon was granted 31,000 stock options with an exercise price of $0.693, vesting over the next year.

Xilio Therapeutics, Inc. Director Christina Rossi was granted 31,000 stock options with an exercise price of $0.693, aligning her interests with shareholder value.

Xilio Therapeutics, Inc. Director Akintunde Olatokumbo Bello was granted 62,000 stock options with an exercise price of $0.70, vesting over three years.